Cellular Biomedicine Group, Inc. today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell therapy for Knee Osteoarthritis , which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.
http://ift.tt/1finbJM
http://ift.tt/1finbJM
No comments:
Post a Comment